Archive: Company News
Company News: ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer
ISA Pharmaceuticals B.V., a clinical-stage immune oncology company, today announced that Gerben Moolhuizen has been promoted from Chief Business Officer to Chief Executive Officer, effective June 1, 2018. He takes over the position from Ronald Loggers, who has served as ISA Pharmaceuticals´ CEO since 2013.
Company News: Curetis Publishes Business and Financial Update for the First Quarter 2018
– Received U.S. FDA clearance for Unyvero System and LRT Cartridge
– Grew revenues in EMEA direct selling markets by 518% vs Q1 2017
– Closed EUR 4.1 million equity offering and gained access to additional USD 10 million equity facility
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the three months ended March 31, 2018.
Company News: Curetis to Hold Annual General Shareholders’ Meeting on June 21, 2018
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today published the invitation to its Annual General Shareholders’ Meeting (“AGM”) 2018.
Company News: ISA Pharmaceuticals Appoints Leon Hooftman as Chief Medical Officer
– Experienced Chief Medical Officer to advance ISA´s clinical pipeline
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Leon Hooftman, MD, to the position of Chief Medical Officer (CMO), effective May 1, 2018. He brings many years of experience in drug development and academic research and has a strong track record in early- and late-stage clinical development with specific expertise in immuno-oncology.